Stockreport

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights [Yahoo! Finance]

Reviva Pharmaceuticals Holdings, Inc.  (RVPH) 
PDF – Initiation of registrational RECOVER-2 trial expected in the second quarter of 2024; topline data expected Q2 2025 – – Topline data from 1-year open-label extension [Read more]